Medical Condition News

RSS

Dye derived from Canary Island lichens may help treat Alzheimer's disease

A red dye derived from lichens that has been used for centuries to color fabrics and food appears to reduce the abundance of small toxic protein aggregates in Alzheimer's disease. The dye, a compound called orcein, and a related substance, called O4, bind preferentially to small amyloid aggregates that are considered to be toxic and cause neuronal dysfunction and memory impairment in Alzheimer's disease.

3 Dec 2011

Promising new agent against sarcomas affecting children

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.

3 Dec 2011

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.

3 Dec 2011

NIAAA awards Rutgers $10M grant to explore genetic links to alcoholism

Rutgers University Cell and DNA Repository (RUCDR) has received a $10 million grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to provide DNA extraction, basic genetic testing, and repository services for more than 46,000 saliva samples, in support of national research efforts to determine the genetic and environmental factors that lead to alcoholism.

3 Dec 2011

University of Illinois Hospital prescribes Tumor Treating Fields therapy for recurrent GBM

The University of Illinois Hospital is the first center in North America to prescribe a new FDA-approved treatment for patients with the most common and aggressive type of brain tumor, glioblastoma multiforme, or GBM.

3 Dec 2011

'Sin tax' on sugary goods may not be efficient, effective

A 'sin tax' applied to sweetened goods on store shelves is not the most efficient, effective method of lowering caloric intake from sweet food and would be more disruptive to consumers than necessary, according to Iowa State University research.

3 Dec 2011

MK 1775 shows promise against sarcomas

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla.

3 Dec 2011

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Obstacles people with type 2 diabetes face that prevent them from getting ultimate treatment

Eli Lilly and Company today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals.

2 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

New insight into why aminoglycoside antibiotics cause deafness

Peter Steyger's research on hearing is very personal. That's because Steyger - a research scientist with the Oregon Hearing Research Center at Oregon Health & Science University - is deaf. Now Steyger has published groundbreaking research that is as personal as it gets. The study gives scientists new insight into why a specific class of antibiotics causes deafness - the same class of antibiotics that caused Steyger's deafness as a child in England 48 years ago. The study was published this month in Scientific Reports, part of the Nature Publishing Group.

2 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

UA researchers receive NSF grant to develop terahertz spectral imager

Researchers at the University of Arizona College of Engineering have been awarded $530,000 to develop a unique piece of scientific equipment that will further spectral imaging research.

2 Dec 2011

GE Healthcare invests in C8 MediSensors to focus on disease management solutions

GE Capital and GE Healthcare, the financial services and healthcare divisions of General Electric Company, announced today an investment in C8 MediSensors, Inc., a privately held developer of non-invasive continuous glucose monitors for diabetic patients.

2 Dec 2011

JDRF supports FDA's draft guidance on artificial pancreas technology

The JDRF today said it is encouraged that the Food and Drug Administration (FDA) has issued a draft guidance which appears to lay a foundation for accelerating the development and availability of artificial pancreas technology (AP) that will improve the lives of millions of Americans living with type 1 diabetes.

2 Dec 2011

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

In a development that could pave the way for treatment for rare neurological diseases and clues to more common ones, physician-scientists at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have secured a grant to establish a clinical site for the Network for Excellence in Neuroscience Clinical Trials.

2 Dec 2011

U.S. Marshals seize all Syntec's dietary supplements for false claims

U.S. Marshals, at the request of the FDA, today seized all dietary supplements by a Wisconsin maker for false claims made about their safety and effectiveness in treating a number of diseases.

2 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.

2 Dec 2011

Novel interventions promote CPAP use among people with OSA

People with obstructive sleep apnea are more likely to stick to prescribed treatment when a partner or parent is involved with their treatment, according to a team of sleep researchers.

2 Dec 2011